|
Refusal to Treat
|
N04.590.233.727.605 |
|
|
Calcium Hydroxide
|
D01.248.497.158.459.150 |
|
|
HLA-DR3 Antigen
|
D23.050.705.552.450.400.440.389.875 |
|
|
HLA-DR Serological Subtypes
|
D23.050.705.552.450.400.440.389 |
|
|
Pulmonary Gas Exchange
|
E01.370.386.700.650 |
|
|
Cerebral Amyloid Angiopathy, Familial
|
C14.907.253.560.200.200.160 |
|
|
Cerebral Amyloid Angiopathy
|
C14.907.253.560.200.200 |
|
|
Cricoid Cartilage
|
A02.165.257.625.211 |
|
|
Laryngeal Cartilages
|
A02.165.257.625 |
|
|
Oximetry
|
E01.370.370.380.600 |
|
|
Complement Activation
|
D003167 |
[The sequential activation of serum COMPLEMENT PROTEINS to create the COMPLEMENT MEMBRANE ATTACK COMPLEX. Factors initiating complement activation include ANTIGEN-ANTIBODY COMPLEXES, microbial ANTIGENS, or cell surface POLYSACCHARIDES.
] |
|
Complement Activating Enzymes
|
D003166 |
[Enzymes that activate one or more COMPLEMENT PROTEINS in the complement system leading to the formation of the COMPLEMENT MEMBRANE ATTACK COMPLEX, an important response in host defense. They are enzymes in the various COMPLEMENT ACTIVATION pathways.
] |
|
Multiple Trauma
|
C26.640 |
|
|
Complement System Proteins
|
D003165 |
[Serum glycoproteins participating in the host defense mechanism of COMPLEMENT ACTIVATION that creates the COMPLEMENT MEMBRANE ATTACK COMPLEX. Included are glycoproteins in the various pathways of complement activation (CLASSICAL COMPLEMENT PATHWAY; ALTERNATIVE COMPLEMENT PATHWAY; and LECTIN COMPLEMENT PATHWAY).
] |
|
Competitive Bidding
|
D003164 |
[Pricing statements presented by more than one party for the purpose of securing a contract.
] |
|
Complement Inactivator Proteins
|
D003169 |
[Serum proteins that negatively regulate the cascade process of COMPLEMENT ACTIVATION. Uncontrolled complement activation and resulting cell lysis is potentially dangerous for the host. The complement system is tightly regulated by inactivators that accelerate the decay of intermediates and certain cell surface receptors.
] |
|
Complement Fixation Tests
|
D003168 |
[Serologic tests based on inactivation of complement by the antigen-antibody complex (stage 1). Binding of free complement can be visualized by addition of a second antigen-antibody system such as red cells and appropriate red cell antibody (hemolysin) requiring complement for its completion (stage 2). Failure of the red cells to lyse indicates that a specific antigen-antibody reaction has taken place in stage 1. If red cells lyse, free complement is present indicating no antigen-antibody reaction occurred in stage 1.
] |
|
Orthodontics
|
H02.163.876.439 |
|
|
Specialties, Dental
|
H02.163.876 |
|
|
Complement Pathway, Alternative
|
D003170 |
[Complement activation initiated by the interaction of microbial ANTIGENS with COMPLEMENT C3B. When COMPLEMENT FACTOR B binds to the membrane-bound C3b, COMPLEMENT FACTOR D cleaves it to form alternative C3 CONVERTASE (C3BBB) which, stabilized by COMPLEMENT FACTOR P, is able to cleave multiple COMPLEMENT C3 to form alternative C5 CONVERTASE (C3BBB3B) leading to cleavage of COMPLEMENT C5 and the assembly of COMPLEMENT MEMBRANE ATTACK COMPLEX.
] |
